Boehringer Ingelheim BI 1305-0014

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)

Key Trial Information

  • Trial Location: NSW
  • Trial Status: Closed to recruitment
  • Trial Type: Interventional
  • Trial Disease Type: Interstitial Lung Disease (ILD)
  • Trial Age Group: Over 18 years
  • Trial Participant Type: Patient